WNT3A and glioblastoma: Since more differentiated GBM cells display higher sensitivity to alkylating agents-based chemotherapy 11, 31, 32, we treated control and Wnt3a pre-treated cells with TMZ and showed that hypoxic Wnt-stimulated GBM cells were significantly sensitized to TMZ treatment (Figure 1D).